Clinical Trial

Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

Study acronym: MINUTE
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study is an interventional, explorative, prospective study to show whether shortening of infusion times for patients using nivolumab, pembrolizumab, ipilimumab, trastuzumab, bevacizumab, durvalumab or atezolizumab continues to be associated with an acceptable safety profile. Infusion times will be gradually shortened if tolerability allowes.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-09-08; most recent amendment 2026-03-25.
Status change: Not Yet Recruiting → Recruiting 2024-03-05
Trial Details
NCT Number NCT06031233
Lead Sponsor Isala
Conditions Oncology, Infusion Reaction
Enrollment 776 participants
Start Date 2023-09-01
Primary Completion 2028-07 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-30